PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-24

Study Completion Date

2026-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 1 study, a single dose of ZTI-01 given to pediatric subjects (under 12 years of age) who require antibiotic therapy to see what the body does to the drug (pharmacokinetics) and to compare if these effects are similar to those observed in adults at a 6g ZTI-01 dose. Study will help establish pediatric dosing in younger children by age cohort. This is a multiple-center, open-label, PK study of ZTI-01 (fosfomycin for injection) single dose scaled by allometric weight-modeling from an adult ZTI-01 dose of 6 grams. Eligible subjects must be receiving standard of care antibiotics for proven or suspected bacterial infection or for peri-operative prophylaxis surgery (in or out of hospital).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

NCT05217537

Bacterial Infections

RECRUITING PHASE1

Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

NCT04040621

Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia

TERMINATED PHASE1

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

NCT02013141

Gram-Positive Bacterial Infections

TERMINATED PHASE1

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

NCT03024034

Bacterial Infections

COMPLETED PHASE1

A Safety and PK Study of IV Eravacycline

NCT03696550

Bacterial Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on pre-dose weight on Day -1, subjects weighing within the 3rd to \< 97th percentile based on age - will receive a single, weight adjusted dose of ZTI-01 via continuous IV infusion or syringe pump over a 1- hour (+10 min) period. Pediatric subjects participating in this study will be assigned to one of three cohorts based on age:

Cohort 1: ≥ 6 years to \<12 years (n=6 PK evaluable subjects) Cohort 2: ≥ 2 years to \<6 years (n=6 PK evaluable subjects)

Cohort 3: Birth to \< 2 years (n=9 PK evaluable subjects), split into 3 subgroups:

(3a) Birth (defined as full term: 37 weeks of gestations or greater) to \< 3 mos, (3b) ≥ 3 mos to \< 6 mos, (3c) ≥ 6 mos to \< 24 months

Cohorts 1 and 2 will be enrolled first with safety and PK data evaluated before enrolling the youngest Cohort 3. Blood for fosfomycin concentration measurement will be collected throughout the study. Safety will be assessed by monitoring adverse and serious adverse events based on medical history, vital signs, ECG, laboratory assessment and physical examination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric ALL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

multiple-center, non-comparative, open-label, PK study

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Subjects \<12 years of age, are assigned by age to one of five age based cohorts. Study is open label and not masked.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ZTI-01 Cohort 1 ≥ 6 to <12 years of age

ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

Group Type EXPERIMENTAL

ZTI-01 100 mg/kg

Intervention Type DRUG

ZTI-01 intravenous (IV)

ZTI-01 Cohort 2 ≥ 2 to <6 years of age

ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

Group Type EXPERIMENTAL

ZTI-01 100 mg/kg

Intervention Type DRUG

ZTI-01 intravenous (IV)

ZTI-01 Cohort 3a Birth to < 3 mos of age

ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

Group Type EXPERIMENTAL

ZTI-01 75 mg/kg

Intervention Type DRUG

ZTI-01 intravenous (IV)

ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age

ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

Group Type EXPERIMENTAL

ZTI-01 100 mg/kg

Intervention Type DRUG

ZTI-01 intravenous (IV)

ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age

ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

Group Type EXPERIMENTAL

ZTI-01 100 mg/kg

Intervention Type DRUG

ZTI-01 intravenous (IV)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZTI-01 100 mg/kg

ZTI-01 intravenous (IV)

Intervention Type DRUG

ZTI-01 75 mg/kg

ZTI-01 intravenous (IV)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IV fosfomycin fosfomycin disodium fosfomycin for injection IV fosfomycin fosfomycin disodium fosfomycin for injection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed consent/assent
* Male or female subjects aged from Birth (defined as full term: 37 weeks of gestation or greater) but less than 12 years old
* Hospitalized, currently receiving antibacterial treatment for confirmed or suspected bacterial infection
* If of reproductive potential, agrees to avoid becoming pregnant or impregnating a partner from the time of consent through 24 hours after completion of study drug administration
* Has sufficient intravascular access to receive study drug through peripheral or central line

Exclusion Criteria

* Has history of known allergy, hypersensitivity, or intolerance to oral or intravenous fosfomycin
* Screening serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3x ULN or total bilirubin \>2x ULN
* Female is post onset of menarche and currently pregnant, or breast feeding, or has a positive serum or urine β-human chorionic gonadotropin (β-hCG) pregnancy test
* Impaired renal function at screening based on the Revised Schwartz Formula using actual body height
* Known infection with immunodeficiency virus (HIV), hepatitis C virus, or hepatitis B virus
* Other laboratory tests, obtained as standard of care, that are outside the normal limits, considered by the Investigator, to be clinically significant
* Have surgery scheduled during collection period of plasma for fosfomycin concentrations
* Weighs outside of the 3rd to less than \<97th percentile based on age
* History of a seizure disorder requiring ongoing treatment with anticonvulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years
* Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) of administration of the study drug
* Has enrolled previously in the current trial or has received ZTI-01 or fosfomycin (IV or oral) for any other reason within the last 30 days
* Is expected to survive less than 72 hours after completion of study drug administration
* Plans to use cardiopulmonary bypass, extracorporeal membrane oxygenation, hemodialysis, or peritoneal dialysis during the study
* Clinically significant abnormalities on the ECG; or have or be at risk for major cardiac events or dysfunction including QTc prolongation, clinically unstable cardiac disease, receipt within 24 hours before the start of study drug of a medication that is labelled to prolong the QT interval, and for breastfed infant subjects only - receipt by the subject's mother within 24 hours before the start of study drug of a medication that is labelled to prolong the QT interval
* Planned blood transfusion within 24 hours of study drug administration or expected before the end of the PK sampling, or has had significant blood loss (≥5% of total blood volume) within 4 weeks before the screening visit
* Any condition that, in the opinion of the PI, would compromise the safety of the subject or the quality of the data
* Subject or caregiver/parent is unable or unwilling to adhere to the study-specified procedures and restrictions

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No